33 results on '"Iwatani, T."'
Search Results
2. Abstract OT2-07-05: A phase III trial to compare eribulin mesylate + trastuzumab (H) + pertuzumab (P) with paclitaxel or docetaxel + HP for HER2-positive advanced or metastatic breast cancer (JBCRG-M06/ EMERALD)
- Author
-
Masuda, N, primary, Yamashita, T, additional, Saji, S, additional, Araki, K, additional, Ito, Y, additional, Takano, T, additional, Takahashi, M, additional, Tsurutani, J, additional, Koizumi, K, additional, Kitada, M, additional, Kojima, Y, additional, Sagara, Y, additional, Tada, H, additional, Iwasa, T, additional, Kadoya, T, additional, Iwatani, T, additional, Hasegawa, H, additional, Morita, S, additional, and Ohno, S, additional
- Published
- 2019
- Full Text
- View/download PDF
3. Abstract OT1-05-04: Phase 3 trial of carboplatin in triple negative breast cancer (TNBC) patients with residual invasive carcinoma after neoadjuvant chemotherapy (JONIE4:J-CAT trial)
- Author
-
Tanino, H, primary, Suzuki, M, additional, Kaise, H, additional, Miyashita, M, additional, Chishima, T, additional, Hayashi, M, additional, Miyoshi, Y, additional, Futamura, M, additional, Ohtani, S, additional, Nagahashi, M, additional, Ohta, T, additional, Kosaka, Y, additional, Ishikawa, T, additional, Hasegawa, Y, additional, Kubota, T, additional, Sangai, T, additional, Iwatani, T, additional, Yamada, A, additional, Akazawa, K, additional, and Kohno, N, additional
- Published
- 2019
- Full Text
- View/download PDF
4. Abstract OT2-01-05: A randomized controlled trial comparing post-operative intensive follow-up with standard follow-up in high-risk breast cancer patients (JCOG1204: INSPIRE)
- Author
-
Hojo, T, primary, Masuda, N, additional, Shibata, T, additional, Mizutani, T, additional, Shien, T, additional, Kinoshita, T, additional, Iwatani, T, additional, Kanbayashi, C, additional, Kitagawa, D, additional, Tsuneizumi, M, additional, and Iwata, H, additional
- Published
- 2019
- Full Text
- View/download PDF
5. PCN349 - CAN WE APPLY THE UTILITY PREDICTION MATHEMATICAL MODEL FOR RECURRENT METASTATIC BREAST CANCER TO JAPANESE PATIENTS?
- Author
-
Iwatani, T., primary and Tsugawa, K., additional
- Published
- 2018
- Full Text
- View/download PDF
6. Correlation Analysis Between Health State Values Derived From EQ-5D-5L And EQ-VAS in Japanese Breast Cancer Patients
- Author
-
Iwatani, T, primary, Noto, S, additional, and Tsugawa, K, additional
- Published
- 2017
- Full Text
- View/download PDF
7. PCN208 - Correlation Analysis Between Health State Values Derived From EQ-5D-5L And EQ-VAS in Japanese Breast Cancer Patients
- Author
-
Iwatani, T, Noto, S, and Tsugawa, K
- Published
- 2017
- Full Text
- View/download PDF
8. Studies of ultra-intense laser plasma interactions for fast ignition
- Author
-
Tanaka, K.A., Kodama, R., Fujita, H., Heya, M., Izumi, N., Kato, Y., Kitagawa, Y., Mima, K., Miyanaga, N., Norimatsu, T., Pukhov, A., Sunahara, A., Takahashi, K., Allen, M., Habara, H., Iwatani, T., Matusita, T., Miyakosi, T., Mori, M., Setoguchi, H., Sonomoto, T., Tanpo, M., Tohyama, S., Azuma, H., Kawasaki, T., Komeno, T., Maekawa, O., Matsuo, S., Shozaki, T., Suzuki, Ka, Yoshida, H., Yamanaka, T., Tanaka, K.A., Kodama, R., Fujita, H., Heya, M., Izumi, N., Kato, Y., Kitagawa, Y., Mima, K., Miyanaga, N., Norimatsu, T., Pukhov, A., Sunahara, A., Takahashi, K., Allen, M., Habara, H., Iwatani, T., Matusita, T., Miyakosi, T., Mori, M., Setoguchi, H., Sonomoto, T., Tanpo, M., Tohyama, S., Azuma, H., Kawasaki, T., Komeno, T., Maekawa, O., Matsuo, S., Shozaki, T., Suzuki, Ka, Yoshida, H., and Yamanaka, T.
- Abstract
Copyright 2000 American Institute of Physics. This article may be downloaded for personal use only. Any other use requires prior permission of the author and the American Institute of Physics. The following article appeared in Physics of Plasmas, 7(5), 2014-2022, 2000 and may be found at http://dx.doi.org/10.1063/1.874023
9. Studies of ultra-intense laser plasma interactions for fast ignition
- Author
-
Tanaka, K.A., Kodama, R., Fujita, H., Heya, M., Izumi, N., Kato, Y., Kitagawa, Y., Mima, K., Miyanaga, N., Norimatsu, T., Pukhov, A., Sunahara, A., Takahashi, K., Allen, M., Habara, H., Iwatani, T., Matusita, T., Miyakosi, T., Mori, M., Setoguchi, H., Sonomoto, T., Tanpo, M., Tohyama, S., Azuma, H., Kawasaki, T., Komeno, T., Maekawa, O., Matsuo, S., Shozaki, T., Suzuki, Ka, Yoshida, H., Yamanaka, T., Tanaka, K.A., Kodama, R., Fujita, H., Heya, M., Izumi, N., Kato, Y., Kitagawa, Y., Mima, K., Miyanaga, N., Norimatsu, T., Pukhov, A., Sunahara, A., Takahashi, K., Allen, M., Habara, H., Iwatani, T., Matusita, T., Miyakosi, T., Mori, M., Setoguchi, H., Sonomoto, T., Tanpo, M., Tohyama, S., Azuma, H., Kawasaki, T., Komeno, T., Maekawa, O., Matsuo, S., Shozaki, T., Suzuki, Ka, Yoshida, H., and Yamanaka, T.
- Abstract
Copyright 2000 American Institute of Physics. This article may be downloaded for personal use only. Any other use requires prior permission of the author and the American Institute of Physics. The following article appeared in Physics of Plasmas, 7(5), 2014-2022, 2000 and may be found at http://dx.doi.org/10.1063/1.874023
10. Eribulin versus S-1 as first or second-line chemotherapy to assess health-related quality of life and overall survival in HER2-negative metastatic breast cancer (RESQ study): a non-inferiority, randomised, controlled, open-label, phase 3 trial.
- Author
-
Takahashi M, Kikawa Y, Kashiwabara K, Taira N, Iwatani T, Shimozuma K, Ohtani S, Yoshinami T, Watanabe J, Kashiwaba M, Watanabe KI, Kitada M, Sakaguchi K, Tanabe Y, Aihara T, and Mukai H
- Abstract
Background: Eribulin prolongs overall survival (OS) of patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC), particularly in later chemotherapy (ChT) treatment. However, the health-related quality of life (HRQoL) and efficacy of first or second-line therapy in eribulin-treated patients remain unknown. Using eribulin in the first- or second-line may demonstrate the non-inferiority of HRQoL compared to S-1, an oral 5-fluorouracil derivative, while maintaining OS., Methods: This randomised, controlled, open-label, phase III trial was conducted at 50 hospitals in Japan. Patients were enrolled from June 2016 and October 2019. Patients with HER2-negative MBC once under or no previous ChT were randomly assigned (1:1) to receive eribulin or S-1. HRQoL was assessed using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) every six weeks until week 24 and every nine weeks until week 42. The primary endpoint was the deterioration defined as more than 10 points worsening of the general health score of QLQ-C30 or death within one year after randomisation. The secondary endpoints included OS. (Trial ID: UMIN000021398)., Findings: Three hundred and two patients were enrolled, with 152 and 148 assigned to the eribulin and S-1 groups, respectively. The questionnaire compliance rate was 85.6%. Risk difference of global health status deterioration through one year was -0.66% (95% CI: -12.47-11.16; non-inferiority P = 0.077) for eribulin compared to S-1 groups. Median time to first deterioration for global health status score was 5.64 (95% CI: 3.51-8.00) and 5.28 months (95% CI: 3.28-7.80) in the eribulin and S-1 groups, respectively. The median OS was 34.7 and 27.8 months, (HR: 0.72, 95% CI: 0.54-0.96; P = 0.026); the median progression-free survival was 7.57 and 6.75 months in the eribulin and S-1 groups, (HR: 0.88, 95% CI: 0.67-1.16; P = 0.35), respectively. No new adverse events occurred., Interpretation: The time of the first clinical deterioration was similar between the two groups and OS significantly increased in eribulin-treated patients., Funding: This study was funded by CSPOR-BC and Eisai CO., Ltd., Competing Interests: KK, TI, KSh, SO, MKi, YT and TA report no coflicts of interest. MT reports honoraria from Astra Zeneca, Daiichi Sankyo, Eisai, Eli Lilly, MSD and Pfizer. YK reports honoraria from Astra Zeneca, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, Pfizer and Taiho. NT reports grant and honoraria from Eisai. TY reports honoraria from Astra Zeneca, Chugai, Eisai, Eli Lilly, Kyowa Kirin, MSD and Pfizer. JW reports grant from Eisai and honoraria from Eisai and Taiho. MKa reports honoraria from Eli Lilly and Pfizer. KW reports honoraria from Astra Zeneca, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, Kyowa Kirin, Novartis, Nippon Kayaku, Pfizer, Shionogi and Taiho. KSa reports honoraria from Eisai and Taiho. HM reports honoraria from Daiichi Sankyo, Taiho and Takeda., (© 2024 The Authors.)
- Published
- 2024
- Full Text
- View/download PDF
11. Optimizing smartphone psychotherapy for depressive symptoms in patients with cancer: Multiphase optimization strategy using a decentralized multicenter randomized clinical trial (J-SUPPORT 2001 Study).
- Author
-
Akechi T, Furukawa TA, Noma H, Iwata H, Toyama T, Higaki K, Matsuoka H, Zenda S, Iwatani T, Akahane K, Inoue A, Sagara Y, Uchida M, Imai F, Momino K, Imaizumi G, Yamaguchi T, Mashiko T, Miyaji T, Horikoshi M, Sakurai N, Onishi T, Kanemitsu Y, Murata T, Wanifuchi-Endo Y, Kuroda H, Nishikawa R, Miyashita M, Abe M, and Uchitomi Y
- Subjects
- Humans, Male, Female, Middle Aged, Adult, Aged, Psychotherapy methods, Outcome Assessment, Health Care, Mobile Applications, Smartphone, Depression therapy, Neoplasms complications, Neoplasms therapy, Cognitive Behavioral Therapy methods
- Abstract
Aim: Patients with cancer experience various forms of psychological distress, including depressive symptoms, which can impact quality of life, elevate morbidity risk, and increase medical costs. Psychotherapy and pharmacotherapy are effective for reducing depressive symptoms among patients with cancer, but most patients prefer psychotherapy. This study aimed to develop an efficient and effective smartphone psychotherapy component to address depressive symptom., Methods: This was a decentralized, parallel-group, multicenter, open, individually randomized, fully factorial trial. Patients aged ≥20 years with cancer were randomized by the presence/absence of three cognitive-behavioral therapy (CBT) skills (behavioral activation [BA], assertiveness training [AT], and problem-solving [PS]) on a smartphone app. All participants received psychoeducation (PE). The primary outcome was change in the patient health questionnaire-9 (PHQ-9) total score between baseline and week 8. Secondary outcomes included anxiety., Results: In total, 359 participants were randomized. Primary outcome data at week 8 were obtained for 355 participants (99%). The week 8 PHQ-9 total score was significantly reduced from baseline for all participants by -1.41 points (95% confidence interval [CI] -1.89, -0.92), but between-group differences in change scores were not significant (BA: -0.04, 95% CI -0.75, 0.67; AT: -0.16, 95% CI -0.87, 0.55; PS: -0.19, 95% CI -0.90, 0.52)., Conclusion: As the presence of any of the three intervention components did not contribute to a significant additive reduction of depressive symptoms, we cannot make evidence-based recommendations regarding the use of specific smartphone psychotherapy., (© 2024 The Authors. Psychiatry and Clinical Neurosciences published by John Wiley & Sons Australia, Ltd on behalf of Japanese Society of Psychiatry and Neurology.)
- Published
- 2024
- Full Text
- View/download PDF
12. Ectopic Breast Cancer Arising within an Axillary Lymph Node.
- Author
-
Toshima K, Shien T, Nishimura MF, Suzuki Y, Nakamoto S, Uno M, Yoshioka R, Tsukioki T, Takahashi Y, Iwamoto T, Iwatani T, and Yanai H
- Subjects
- Female, Humans, Aged, Mastectomy, Lymph Nodes pathology, Breast, Lymph Node Excision, Breast Neoplasms pathology, Choristoma surgery, Choristoma pathology
- Abstract
We report our experience with the diagnosis and treatment of an ectopic breast cancer arising within an axillary lymph node. The patient was a 65-year-old woman diagnosed breast cancer and axillary lymph node metastasis. We performed a partial mastectomy and axillary lymph node dissection. Postoperative pathology revealed no malignant lesions in the breast; however, a nodule in one of axillary lymph nodes had mixed benign and malignant components, leading to a diagnosis of invasive ductal carcinoma derived from ectopic mammary tissue. This case represents a very rare form of breast cancer, and the malignancy was difficult to distinguish from metastasis., Competing Interests: No potential conflict of interest relevant to this article was reported.
- Published
- 2024
- Full Text
- View/download PDF
13. Surgical site infections in thyroid and parathyroid surgery in Japan: An analysis of the Japan Nosocomial Infections Surveillance database from 2013 to 2020.
- Author
-
Iwatani T and Saito S
- Subjects
- Humans, Antibiotic Prophylaxis methods, Databases, Factual, Incidence, Japan epidemiology, Population Surveillance, Risk Factors, Cross Infection epidemiology, Cross Infection microbiology, Cross Infection prevention & control, Parathyroid Glands surgery, Surgical Wound Infection epidemiology, Surgical Wound Infection microbiology, Surgical Wound Infection prevention & control, Thyroid Gland surgery
- Abstract
Surgical site infections (SSIs) after thyroid surgery are rare complications, with incidence rates of 0.3%-1.6%. Using a Japanese database, we conducted exploratory analyses on the incidence of SSIs, investigated the incidence of SSIs by the National Nosocomial Infections Surveillance risk index, and identified the causative bacteria of SSIs. SSIs occurred in 50 (0.7%) of 7388 thyroid surgery cases. Risk index-0 patients had the lowest incidence rate of SSIs (0.41%). The incidence of SSIs in risk index-1 patients was 3.05 times the incidence of SSIs in risk index-0 patients. The rate of SSI occurrence for risk index-2 patients was 4.22 times the rate of SSI occurrence for risk index-0 patients. Thirty-one bacterial species were identified as the cause of SSIs in thyroid surgery cases, of which 12 (38.7%) SSIs were caused by Staphylococcus aureus and Staphylococcus epidermidis. Of the nine SSIs caused by Staphylococcus aureus, 55.6% (five cases) were attributed to methicillin-resistant Staphylococcus aureus. Therefore, routine prophylactic antibiotic administration should be avoided, while the target for administration should be narrowed, according to the SSI risk. Administration of prophylactic antibiotics, such as 2 g piperacillin or 1 g cefazolin, is considered appropriate., (© 2022 The Authors. International Wound Journal published by Medicalhelplines.com Inc (3M) and John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
14. Optimization of smartphone psychotherapy for depression and anxiety among patients with cancer using the multiphase optimization strategy (MOST) framework and decentralized clinical trial system (SMartphone Intervention to LEssen depression/Anxiety and GAIN resilience: SMILE AGAIN project): a protocol for a randomized controlled trial.
- Author
-
Uchida M, Furukawa TA, Yamaguchi T, Imai F, Momino K, Katsuki F, Sakurai N, Miyaji T, Horikoshi M, Iwata H, Zenda S, Iwatani T, Ogawa A, Inoue A, Abe M, Toyama T, Uchitomi Y, Matsuoka H, Noma H, and Akechi T
- Subjects
- Humans, Depression diagnosis, Depression therapy, Quality of Life, Treatment Outcome, Psychotherapy, Anxiety diagnosis, Anxiety therapy, Randomized Controlled Trials as Topic, Multicenter Studies as Topic, Smartphone, Neoplasms therapy
- Abstract
Background: Cancer patients experience various forms of psychological distress. Their distress, mainly in the form of depression and anxiety, leads to poor quality of life, increased medical spending due to frequent visits, and decrease in treatment adherence. It is estimated that 30-50% among them would require support from mental health professionals: in reality, much less actually receive such support partly due to a shortage of qualified professionals and also due to psychological barriers in seeking such help. The purpose of the present study is to develop the easily accessible and the most efficient and effective smartphone psychotherapy package to alleviate depression and anxiety in cancer patients., Methods: Based on the multiphase optimization strategy (MOST) framework, the SMartphone Intervention to LEssen depression/Anxiety and GAIN resilience project (SMILE-AGAIN project) is a parallel-group, multicenter, open, stratified block randomized, fully factorial trial with four experimental components: psychosocial education (PE), behavioral activation (BA), assertion training (AT), and problem-solving therapy (PS). The allocation sequences are maintained centrally. All participants receive PE and then are randomized to the presence/absence of the remaining three components. The primary outcome of this study is the Patient Health Questionnaire-9 (PHQ-9) total score, which will be administered as an electronic patient-reported outcome on the patients' smartphones after 8 weeks. The protocol was approved by the Institutional Review Board of Nagoya City University on July 15, 2020 (ID: 46-20-0005). The randomized trial, which commenced in March 2021, is currently enrolling participants. The estimated end date for this study is March 2023., Discussion: The highly efficient experimental design will allow for the identification of the most effective components and the most efficient combinations among the four components of the smartphone psychotherapy package for cancer patients. Given that many cancer patients face significant psychological hurdles in seeing mental health professionals, easily accessible therapeutic interventions without hospital visits may offer benefits. If an effective combination of psychotherapy is determined in this study, it can be provided using smartphones to patients who cannot easily access hospitals or clinics., Trial Registration: UMIN000041536, CTR. Registered on 1 November 2020 https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000047301 ., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
15. Patient-reported outcome and quality of life research policy: Japan Clinical Oncology Group (JCOG) policy.
- Author
-
Ishiki H, Kikawa Y, Terada M, Mizusawa J, Honda M, Iwatani T, Mizutani T, Mori K, Nakamura N, Miyaji T, Yamaguchi T, Ando M, Nakamura K, Fukuda H, and Kiyota N
- Subjects
- Humans, Japan, Medical Oncology, Policy, Quality of Life, Neoplasms therapy
- Abstract
Assessments of patient-reported outcomes and health-related quality of life in cancer clinical trials have been increasingly emphasized recently because patient and public involvement in cancer treatment development has been promoted by regulatory authorities and academic societies. To assess patient experiences during and after cancer treatment, there is interest in implementing patient-reported outcome and health-related quality of life assessments into cancer clinical trials. The Japan Clinical Oncology Group quality of life ad hoc committee previously created a version of the Quality of Life Assessment Policy in 2006. Recently, there has been increasing demand from Japan Clinical Oncology Group researchers to assess patient-reported outcome/health-related quality of life in clinical trials. Although guidelines are available regarding planning and reporting clinical trials that include patient-reported outcome/health-related quality of life as an endpoint, there are still issues regarding the lack of consensus on standardized methods for analysing and interpreting the results. Hence, it was considered necessary to reorganize the Japan Clinical Oncology Group patient-reported outcome/quality of life research committee and to revise the former patient-reported outcome/quality of life research policy to promote patient-reported outcome/health-related quality of life research in future Japan Clinical Oncology Group trials. The purpose of this Japan Clinical Oncology Group patient-reported outcome/quality of life research policy is to define patient-reported outcome/health-related quality of life research and provide guidelines for including patient-reported outcome/health-related quality of life as an endpoint in Japan Clinical Oncology Group trials., (© The Author(s) 2023. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permission@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF
16. A Case of Brachial Lymph Node Recurrences after the Resection of Locally Advanced Breast Cancer.
- Author
-
Onishi K, Watanuki R, Yokoe T, Iwatani T, Yamauchi C, and Onishi T
- Abstract
We present a case of two recurrences in the brachial lymph nodes after initial resection, which was performed for radical cure. A 66-year-old woman was diagnosed with left breast cancer T4bN3cM0 Stage IIIC and an immunohistochemistry assay showed estrogen receptor (ER) positivity (5%), progesterone-receptor (PgR) positivity (1%), human epidermal growth factor receptor-2 (HER2) positivity (3+), and low Ki-67 (15%). After four courses of adriamycin and cyclophosphamide, followed by four courses of trastuzumab plus docetaxel, the patient underwent left mastectomy and axillary dissection. Postoperatively, she was diagnosed with breast cancer ypT1cN0M0, and trastuzumab and anastrozole were started. Postoperative irradiation was performed. Three years and 5 months after the initial breast cancer surgery, she had left brachial lymph node recurrence. It was resected, and tamoxifen was administered postoperatively. One year and 9 months after, she had another left brachial lymph node recurrence, and it was resected. She received radiation therapy to her upper limb and started taking exemestane. After 1 year and 3 months since the second recurrence surgery, there has been no recurrence. Our case suggests that the replacement of regional lymph nodes with tumor cells may result in the reconstruction of lymph flow to the upper arm and the development of brachial lymph node metastasis. There are no reports of resection of the recurrent tumor in the brachial lymph node for curative treatment. Therefore, careful follow-up is important in the future., Competing Interests: Tsuguo Iwatani received lecture fees from Eli Lilly, Asahi Kasei Medical, Novartis, and Pfizer. All remaining authors have no conflicts of interest to declare., (Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel.)
- Published
- 2022
- Full Text
- View/download PDF
17. Pathologic method for extracting good prognosis group in triple-negative breast cancer after neoadjuvant chemotherapy.
- Author
-
Eguchi Y, Nakai T, Kojima M, Wakabayashi M, Sakamoto N, Sakashita S, Miyazaki S, Taki T, Watanabe R, Watanuki R, Yamauchi C, Iwatani T, Mukohara T, Onishi T, and Ishii G
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Humans, Neoadjuvant Therapy methods, Neoplasm, Residual pathology, Prognosis, Retrospective Studies, Rectal Neoplasms drug therapy, Triple Negative Breast Neoplasms drug therapy, Triple Negative Breast Neoplasms pathology
- Abstract
The area of residual tumor (ART) is a prognostic factor in patients treated with neoadjuvant chemotherapy (NAC) for lung, pancreatic, and rectal cancers. This study aimed to evaluate the usefulness of ART as a method for predicting the prognosis of triple-negative breast cancer (TNBC) patients after NAC. We included 143 patients with TNBC treated with NAC. The ART at the maximum cut surface of the residual tumor was measured. We divided the patients into three groups: ART-0 (ART = 0 mm
2 ), ART-low (0 mm2 < ART ≤ 136mm2 ), and ART-high (ART > 136 mm2 ), and compared their clinicopathologic factors and prognosis. There were no significant differences in either recurrence-free survival (RFS) or overall survival (OS) between ART-0 and ART-low; however, the ART-high group had significantly shorter RFS and OS than the ART-0 and ART-low groups. Multivariate analysis showed that ART-0 and -low and ypN(-) were independent favorable prognostic factors for RFS. Groups with both ART-low and ypN(-) as well as those with ART-0 and ypN(-) showed significantly longer OS and RFS than the other groups (P < .05). Moreover, there was no significant difference in the RFS and OS between the ART-0 and ypN(-) groups and the ART-low and ypN(-) groups (P = .249 and P = .554, respectively). We concluded that ART is a candidate histopathological evaluation method for predicting the prognosis of TNBC patients treated with NAC. Furthermore, postoperative chemotherapy could be omitted in patients with ART-0 and ypN(-) (pathological complete response) and those with ART-low and ypN(-)., (© 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.)- Published
- 2022
- Full Text
- View/download PDF
18. Validation of the predictive accuracy of health-state utility values based on the Lloyd model for metastatic or recurrent breast cancer in Japan.
- Author
-
Iwatani T, Inoue E, and Tsugawa K
- Subjects
- Cost-Benefit Analysis, Female, Humans, Japan, Quality of Life, Quality-Adjusted Life Years, Surveys and Questionnaires, Breast Neoplasms
- Abstract
Introduction: Although there is a lack of data on health-state utility values (HSUVs) for calculating quality-adjusted life-years in Japan, cost-utility analysis has been introduced by the Japanese government to inform decision making in the medical field since 2016., Objectives: This study aimed to determine whether the Lloyd model which was a predictive model of HSUVs for metastatic breast cancer (MBC) patients in the UK can accurately predict actual HSUVs for Japanese patients with MBC., Design: The prospective observational study followed by the validation study of the clinical predictive model., Setting and Participants: Forty-four Japanese patients with MBC were studied at 336 survey points., Methods: This study consisted of two phases. In the first phase, we constructed a database of clinical data prospectively and HSUVs for Japanese patients with MBC to evaluate the predictive accuracy of HSUVs calculated using the Lloyd model. In the second phase, Bland-Altman analysis was used to determine how accurately predicted HSUVs (based on the Lloyd model) correlated with actual HSUVs obtained using the EuroQol 5-Dimension 5-Level questionnaire, a preference-based measure of HSUVs in patients with MBC., Results: In the Bland-Altman analysis, the mean difference between HSUVs estimated by the Lloyd model and actual HSUVs, or systematic error, was -0.106. The precision was 0.165. The 95% limits of agreement ranged from -0.436 to 0.225. The t value was 4.6972, which was greater than the t value with 2 degrees of freedom at the 5% significance level (p=0.425)., Conclusions: There were acceptable degrees of fixed and proportional errors associated with the prediction of HSUVs based on the Lloyd model for Japanese patients with MBC. We recommend that sensitivity analysis be performed when conducting cost-effectiveness analyses with HSUVs calculated using the Lloyd model., Competing Interests: Competing interests: KT received honoraria from AstraZeneca, Chugai Pharmaceutical, Daiichi Sankyo, Eizai, Eli Lilly Japan KK, Nippon Kayaku, Pfizer, Taiho Pharmaceutical and Takeda Pharmaceutical., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2021
- Full Text
- View/download PDF
19. Changes in Health State Utility Values in Japanese Patients with End-Stage Breast Cancer.
- Author
-
Iwatani T, Noto S, and Tsugawa K
- Subjects
- Cost-Benefit Analysis, Female, Humans, Japan, Breast Neoplasms
- Abstract
We aimed to determine the dynamic trends in health state utility values (HSUVs) in patients with end-stage breast cancer. We selected 181 patients comprising 137 with primary breast cancer (PBC) and 44 with metastatic breast cancer (MBC) (28 survivors and 16 patients with MBC death). HSUVs were 0.90 and 0.89 in patients with PBC and 0.83 and 0.80 in those with MBC (survivors) at 6 and 3 months, respectively, before the end of the observation period; these values were 0.73 and 0.66, respectively, in those with MBC (deceased) during the aforementioned period. The root-mean-squared error (RMSE) for the decrease in HSUVs over 3 months was 0.10, 0.096, and 0.175 for patients with PBC, MBC (survivors), and MBC (deceased), respectively. One-way analysis of variance for differences in absolute error among the groups was significant ( p = 0.0102). Multiple comparisons indicated a difference of 0.068 in absolute error between patients with PBC and those with MBC (deceased) ( p = 0.0082). Patients with end-stage breast cancer had well-controlled HSUVs 3 months before death, with a sharp decline in HSUVs in the 3 months leading up to death.
- Published
- 2021
- Full Text
- View/download PDF
20. In Vitro Production of Coenzyme A Using Thermophilic Enzymes.
- Author
-
Suryatin Alim G, Iwatani T, Okano K, Kitani S, and Honda K
- Subjects
- Bacterial Proteins metabolism, Coenzyme A biosynthesis, Phosphotransferases (Alcohol Group Acceptor) metabolism, Thermus thermophilus enzymology
- Abstract
Coenzyme A (CoA) is an essential cofactor present in all domains of life and is involved in numerous metabolic pathways, including fatty acid metabolism, pyruvate oxidation through the tricarboxylic acid (TCA) cycle, and the production of secondary metabolites. This characteristic makes CoA a commercially valuable compound in the pharmaceutical, cosmetic, and clinical industries. However, CoA is difficult to accumulate in living cells at a high level, since it is consumed in multiple metabolic pathways, hampering its manufacturing by typical cell cultivation and extraction approaches. The feedback inhibition by CoA to a biosynthetic enzyme, pantothenate kinase (PanK), is also a serious obstacle for the high-titer production of CoA. To overcome this challenge, in vitro production of CoA, in which the CoA biosynthetic pathway was reconstructed outside cells using recombinant thermophilic enzymes, was performed. The in vitro pathway was designed to be insensitive to the feedback inhibition of CoA using CoA-insensitive type III PanK from the thermophilic bacterium Thermus thermophilus. Furthermore, a statistical approach using design of experiments (DOE) was employed to rationally determine the enzyme loading ratio to maximize the CoA production rate. Consequently, 0.94 mM CoA could be produced from 2 mM d-pantetheine through the designed pathway. We hypothesized that the insufficient conversion yield is attributed to the high K
m value of T. thermophilus PanK toward ATP. Based on these observations, possible CoA regulation mechanisms in T. thermophilus and approaches to improve the feasibility of CoA production through the in vitro pathway have been investigated. IMPORTANCE The biosynthesis of coenzyme A (CoA) in bacteria and eukaryotes is regulated by feedback inhibition targeting type I and type II pantothenate kinase (PanK). Type III PanK is found only in bacteria and is generally insensitive to CoA. Previously, type III PanK from the hyperthermophilic bacterium Thermotoga maritima was shown to defy this typical characteristic and instead shows inhibition toward CoA. In the present study, phylogenetic analysis combined with functional analysis of type III PanK from thermophiles revealed that the CoA-sensitive behavior of type III PanK from T. maritima is uncommon. We cloned type III PanKs from Thermus thermophilus and Geobacillus sp. strain 30 and showed that neither enzyme's activities were inhibited by CoA. Furthermore, we utilized type III PanK for a one-pot cascade reaction to produce CoA.- Published
- 2021
- Full Text
- View/download PDF
21. Genomic profiling reveals heterogeneous populations of ductal carcinoma in situ of the breast.
- Author
-
Nagasawa S, Kuze Y, Maeda I, Kojima Y, Motoyoshi A, Onishi T, Iwatani T, Yokoe T, Koike J, Chosokabe M, Kubota M, Seino H, Suzuki A, Seki M, Tsuchihara K, Inoue E, Tsugawa K, Ohta T, and Suzuki Y
- Subjects
- Adult, Age Factors, Aged, Aged, 80 and over, Female, GATA3 Transcription Factor genetics, GATA3 Transcription Factor metabolism, Gene Expression Profiling, Humans, Middle Aged, Receptor, ErbB-2 genetics, Receptor, ErbB-2 metabolism, Young Adult, Breast Neoplasms genetics, Carcinoma, Intraductal, Noninfiltrating genetics, Gene Amplification, Mutation
- Abstract
In a substantial number of patients, ductal carcinoma in situ (DCIS) of the breast will never progress to invasive ductal carcinoma, and these patients are often overtreated under the current clinical criteria. Although various candidate markers are available, relevant markers for delineating risk categories have not yet been established. In this study, we analyzed the clinical characteristics of 431 patients with DCIS and performed whole-exome sequencing analysis in a 21-patient discovery cohort and targeted deep sequencing analysis in a 72-patient validation cohort. We determined that age <45 years, HER2 amplification, and GATA3 mutation are possible indicators of relapse. PIK3CA mutation negativity and PgR negativity were also suggested to be risk factors. Spatial transcriptome analysis further revealed that GATA3 dysfunction upregulates epithelial-to-mesenchymal transition and angiogenesis, followed by PgR downregulation. These results reveal the existence of heterogeneous cell populations in DCIS and provide predictive markers for classifying DCIS and optimizing treatment.
- Published
- 2021
- Full Text
- View/download PDF
22. Current Status of Advance Care Planning and End-of-life Communication for Patients with Advanced and Metastatic Breast Cancer.
- Author
-
Sagara Y, Mori M, Yamamoto S, Eguchi K, Iwatani T, Naito Y, Kogawa T, Tanaka K, Kotani H, Yasojima H, Ozaki Y, Noguchi E, Miyasita M, Kondo N, Niikura N, Toi M, Shien T, and Iwata H
- Subjects
- Adult, Communication, Death, Female, Humans, Advance Care Planning, Breast Neoplasms therapy, Terminal Care
- Abstract
Background: Advance care planning (ACP) is a process that supports adults in understanding and sharing their personal values, life goals, and preferences regarding future medical care. We examined the current status of ACP and end-of-life (EOL) communication between oncologists and patients with metastatic breast cancer., Materials and Methods: We conducted a survey among 41 institutions that specialize in oncology by using an online tool in October 2019. Participants (118 physicians) from 38 institutions completed a 39-item questionnaire that measured facility type and function; physicians' background and clinical approach, education about EOL communication, and understanding about ACP; and the current situation of ACP and EOL discussions., Results: Ninety-eight responses concerning physicians' engagement in ACP with patients were obtained. Seventy-one (72%) answered that they had engaged in ACP. Among these, 23 (33%) physicians used a structured format to facilitate the conversation in their institutions, and only 6 (8%) settled triggers or sentinel events for the initiation of ACP. In the multivariable analysis, only the opportunity to learn communication skills was associated with physicians' engagement with ACP (odds ratio: 2.8, 95% confidence interval: 1.1-7.0). The frequency and timing of communication about ACP and EOL care with patients substantially varied among the oncologists. Communication about patients' life expectancy was less frequent compared with other topics., Conclusion: The opportunity to improve EOL communication skills promoted physicians' engagement with ACP among patients with metastatic/advanced breast cancer. However, there were still substantial variabilities in the method, frequency, and timing of ACP and EOL communication among the oncologists., Implications for Practice: This study found that the opportunity to improve end-of-life (EOL) communication skills promoted physicians' engagement in advance care planning (ACP) among patients with metastatic/advanced breast cancer. All oncologists who treat said patients are encouraged to participate in effective education programs concerning EOL communication skills. In clinical practice, there are substantial variabilities in the method, frequency, and timing of ACP and EOL communication among oncologists. As recommended in several clinical guidelines, the authors suggest a system that identifies patients who require conversations about their care goals, a structured format to facilitate the conversations, and continuous measurement for improving EOL care and treatment., (© 2020 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.)
- Published
- 2021
- Full Text
- View/download PDF
23. Prospective observational study estimating willingness-to-pay for breast cancer treatments through contingent valuation method in Japanese breast cancer patients (JCOG1709A).
- Author
-
Iwatani T, Hara F, Shien T, Sasaki K, Katayama H, Fukuda H, Shiroiwa T, and Iwata H
- Subjects
- Cost-Benefit Analysis, Female, Humans, Japan, Middle Aged, Probability, Prospective Studies, Surveys and Questionnaires, Breast Neoplasms economics, Breast Neoplasms therapy
- Abstract
In April 2016, the Japanese government introduced health technology assessment as a response to rising medical expenses due to 'medical innovation'. This study investigates how Japanese breast cancer patients who received treatment in Japan consider the financial value (willingness-to-pay; WTP) for their life and health by using the contingent valuation method (CVM) prospectively. First, 168 patients (84 primary breast cancer patients and 84 metastatic breast cancer patients) were pre-examined their WTP with dichotomous-choice method survey form. Next, 1,596 patients (798 primary breast cancer patients and 798 metastatic breast cancer patients) will be surveyed to their WTP for hypothetical scenarios in CVM. Based on our results, we will construct an evaluation axis from the patients' viewpoint for the cost-effectiveness of clinical trials to establish standard treatments for breast cancer. We believe this research can contribute to create a meaningful healthcare system for patients, clinicians, industries, and healthcare policymakers., (© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permission@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
24. Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD).
- Author
-
Yamashita T, Masuda N, Saji S, Araki K, Ito Y, Takano T, Takahashi M, Tsurutani J, Koizumi K, Kitada M, Kojima Y, Sagara Y, Tada H, Iwasa T, Kadoya T, Iwatani T, Hasegawa H, Morita S, and Ohno S
- Abstract
An amendment to this paper has been published and can be accessed via the original article.
- Published
- 2020
- Full Text
- View/download PDF
25. Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD).
- Author
-
Yamashita T, Masuda N, Saji S, Araki K, Ito Y, Takano T, Takahashi M, Tsurutani J, Koizumi K, Kitada M, Kojima Y, Sagara Y, Tada H, Iwasa T, Kadoya T, Iwatani T, Hasegawa H, Morita S, and Ohno S
- Subjects
- Adult, Aged, Antibodies, Monoclonal, Humanized administration & dosage, Antibodies, Monoclonal, Humanized therapeutic use, Antineoplastic Agents, Immunological administration & dosage, Antineoplastic Agents, Immunological therapeutic use, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms pathology, Bridged-Ring Compounds administration & dosage, Bridged-Ring Compounds therapeutic use, Bridged-Ring Compounds toxicity, Female, Furans administration & dosage, Furans therapeutic use, Humans, Japan epidemiology, Ketones administration & dosage, Ketones therapeutic use, Middle Aged, Progression-Free Survival, Quality of Life, Stroke Volume physiology, Taxoids administration & dosage, Taxoids therapeutic use, Taxoids toxicity, Trastuzumab administration & dosage, Trastuzumab therapeutic use, Tubulin Modulators administration & dosage, Tubulin Modulators therapeutic use, Ventricular Function, Left physiology, Breast Neoplasms metabolism, Breast Neoplasms secondary, Neoplasm Metastasis drug therapy, Receptor, ErbB-2 metabolism
- Abstract
Background: Trastuzumab (Tmab), pertuzumab (Pmab), and taxane has been a standard first-line treatment for recurrent or metastatic human epidermal growth factor (HER2)-positive breast cancer (HER2
+ mBC) but has some safety issues due to taxane-induced toxicities. This has led to ongoing efforts to seek less toxic alternatives to taxanes that are equally effective when used in combination with Tmab plus Pmab. This study aims to show the non-inferiority of eribulin, a non-taxane microtubule inhibitor, against taxane, as a partner for dual HER2 blockade., Methods/design: This multicenter, randomized, open-label, parallel-group, phase III study will involve a total of 480 Japanese women with HER2+ mBC who meet the following requirements: (1) age 20-70 years; (2) no prior cytotoxic chemotherapy (excluding trastuzumab-emtansine) for mBC; (3) ≥ 6 months after prior neoadjuvant or adjuvant cytotoxic chemotherapy; (4) presence of any radiologically evaluable lesion; (5) left ventricular ejection fraction ≥ 50%; (6) Eastern Cooperative Oncology Group performance status score of 0 or 1; (7) adequate organ function; and (8) life expectancy of at least 6 months. They will be randomized 1:1 to receive eribulin (1.4 mg/m2 on days 1 and 8) or taxane (docetaxel 75 mg/m2 on day 1 or paclitaxel 80 mg/m2 on days 1, 8, and 15) in combination with Tmab (8 mg/kg then 6 mg/kg) plus Pmab (840 mg then 420 mg) on day 1 of each 21-day cycle. The treatment will be continued until disease progression or unmanageable toxicity. The primary endpoint is progression-free survival as per investigator according to RECIST v1.1 criteria. Key secondary endpoints include objective response rate, overall survival, quality of life and safety. Non-inferiority will be tested with two margins of 1.33 and 1.25 in a stepwise manner. If non-inferiority is shown with a margin of 1.25, superiority will then be tested., Discussion: If this study shows the non-inferiority, or even superiority, of Tmab, Pmab, and eribulin against the existing taxane-containing regimen, this new regimen may become a standard first- or second-line treatment option for HER2+ mBC in Japan., Trial Registration: ClinicalTrials.gov, ID: NCT03264547. Registered on 28 June 2017.- Published
- 2020
- Full Text
- View/download PDF
26. Clinicopathological Significance of TARBP2, APP, and ZNF395 in Breast Cancer.
- Author
-
Oi R, Koizumi H, Maeda I, Noguchi A, Tatsunami S, Iwatani T, Kawamoto H, Tsugawa K, and Takagi M
- Abstract
The double-stranded RNA-binding protein TARBP2 has been suggested to act as an upstream regulator of breast cancer metastasis by destabilizing transcripts of the possible metastasis suppressors amyloid precursor protein (APP) and ZNF395. We examined this hypothesis by immunostaining of TARBP2, APP, and ZNF395 in 200 breast cancer specimens using tissue microarrays and analyzed the relationships between expression levels and clinicopathological parameters and prognosis. Increased TARBP2 overexpression was associated with shorter overall survival and disease-free survival, and increased but not reduced APP expression correlated with lower overall survival and disease-free survival. ZNF395 expression levels had no prognostic value, but reduced expression correlated with reduced lymph node metastasis. There was no significant relationship between TARBP2 overexpression and reduced APP and/or ZNF395 expression. Patients with tumors with higher TARBP2 or APP expression had unfavorable prognoses. Although reduced ZNF395 expression was significantly related to reduced lymph node metastasis, further studies are needed to clarify the role of TARBP2/APP/ZNF395 in breast cancer., Competing Interests: Authors disclose no potential conflicts of interest.
- Published
- 2016
- Full Text
- View/download PDF
27. The safety of chemotherapy for breast cancer patients with hepatitis C virus infection.
- Author
-
Miura Y, Theriault RL, Naito Y, Suyama K, Shimomura A, Iwatani T, Miura D, Kawabata H, Kumada H, and Takano T
- Abstract
Background: Hepatitis C virus (HCV) infection is one of the major causes of chronic liver disease, and more than 880,000 people are estimated to be infected with HCV in Japan. Little information is available on the outcomes of HCV during chemotherapy for solid tumors, and the impact of HCV infection on toxicity of chemotherapy is unknown., Materials and Methods: We performed a retrospective survey of 1,110 patients diagnosed with breast cancer between January 2006 and March 2011 at our institution. All patients had been screened for hepatitis C serology at diagnosis of breast cancer. We retrospectively investigated the change in HCV load and the toxicities of chemotherapy, based on review of their medical records., Results: 23 patients were identified as having a positive test for anti-HCV antibodies. Ten of these patients received chemotherapy. Their median age was 66 years. No patient had decompensated liver disease at baseline. Eight patients received cytotoxic agents with or without trastuzumab, and two patients received trastuzumab alone. Four of eight patients who received cytotoxic chemotherapy developed febrile neutropenia and one developed transaminases elevation. Serum HCV-ribonucleic acid (RNA) level before and after chemotherapy was evaluated in six patients. Median serum HCV-RNA level at baseline and after chemotherapy was 6.5 and 6.7 logIU/ml, respectively., Conclusion: Chemotherapy for breast cancer patients with HCV infection is feasible, and viral load doesn't change during the chemotherapy.
- Published
- 2013
- Full Text
- View/download PDF
28. Glucuronyltransferase activity of KfiC from Escherichia coli strain K5 requires association of KfiA: KfiC and KfiA are essential enzymes for production of K5 polysaccharide, N-acetylheparosan.
- Author
-
Sugiura N, Baba Y, Kawaguchi Y, Iwatani T, Suzuki K, Kusakabe T, Yamagishi K, Kimata K, Kakuta Y, and Watanabe H
- Subjects
- Acetylglucosamine metabolism, Amino Acid Sequence, Antigens, Bacterial biosynthesis, Bioengineering, Enzyme Activation, Escherichia coli genetics, Escherichia coli metabolism, Escherichia coli Proteins biosynthesis, Escherichia coli Proteins chemistry, Escherichia coli Proteins genetics, Glycosyltransferases biosynthesis, Glycosyltransferases chemistry, Glycosyltransferases genetics, Heparitin Sulfate metabolism, Molecular Sequence Data, N-Acetylglucosaminyltransferases biosynthesis, N-Acetylglucosaminyltransferases chemistry, N-Acetylglucosaminyltransferases genetics, Point Mutation, Polymers metabolism, Recombinant Proteins biosynthesis, Recombinant Proteins chemistry, Recombinant Proteins genetics, Recombinant Proteins metabolism, Escherichia coli enzymology, Escherichia coli Proteins metabolism, Glucuronosyltransferase metabolism, Glycosaminoglycans biosynthesis, Glycosyltransferases metabolism, N-Acetylglucosaminyltransferases metabolism
- Abstract
Heparan sulfate is a ubiquitous glycosaminoglycan in the extracellular matrix of most animals. It interacts with various molecules and exhibits important biological functions. K5 antigen produced by Escherichia coli strain K5 is a linear polysaccharide N-acetylheparosan consisting of GlcUA beta1-4 and GlcNAc alpha1-4 repeating disaccharide, which forms the backbone of heparan sulfate. Region 2, located in the center of the K5-specific gene cluster, encodes four proteins, KfiA, KfiB, KfiC, and KfiD, for the biosynthesis of the K5 polysaccharide. Here, we expressed and purified the recombinant KfiA and KfiC proteins and then characterized these enzymes. Whereas the recombinant KfiC alone exhibited no GlcUA transferase activity, it did exhibit GlcUA transferase and polymerization activities in the presence of KfiA. In contrast, KfiA had GlcNAc transferase activity itself, which was unaffected by the presence of KfiC. The GlcNAc and GlcUA transferase activities were analyzed with various truncated and point mutants of KfiA and KfiC. The point mutants replacing aspartic acid of a DXD motif and lysine and glutamic acid of an ionic amino acid cluster, and the truncated mutants deleting the C-terminal and N-terminal sites, revealed the essential regions for GlcNAc and GlcUA transferase activity of KfiC and KfiA, respectively. The interaction of KfiC with KfiA is necessary for the GlcUA transferase activity of KfiC but not for the enzyme activity of KfiA. Together, these results indicate that the complex of KfiA and KfiC has polymerase activity to synthesize N-acetylheparosan, providing a useful tool toward bioengineering of defined heparan sulfate chains.
- Published
- 2010
- Full Text
- View/download PDF
29. Crystal structure of alpha/beta-galactoside alpha2,3-sialyltransferase from a luminous marine bacterium, Photobacterium phosphoreum.
- Author
-
Iwatani T, Okino N, Sakakura M, Kajiwara H, Takakura Y, Kimura M, Ito M, Yamamoto T, and Kakuta Y
- Subjects
- Bacterial Proteins genetics, Bacterial Proteins metabolism, Catalytic Domain, Crystallography, X-Ray, Cytidine Monophosphate metabolism, Cytidine Monophosphate N-Acetylneuraminic Acid metabolism, Galactosides metabolism, Models, Molecular, Photobacterium genetics, Protein Conformation, Recombinant Proteins chemistry, Recombinant Proteins genetics, Recombinant Proteins metabolism, Sialyltransferases genetics, Sialyltransferases metabolism, Static Electricity, Substrate Specificity, beta-Galactoside alpha-2,3-Sialyltransferase, Bacterial Proteins chemistry, Photobacterium enzymology, Sialyltransferases chemistry
- Abstract
Alpha/beta-galactoside alpha2,3-sialyltransferase produced by Photobacterium phosphoreum JT-ISH-467 is a unique enzyme that catalyzes the transfer of N-acetylneuraminic acid residue from cytidine monophosphate N-acetylneuraminic acid to acceptor carbohydrate groups. The enzyme recognizes both mono- and di-saccharides as acceptor substrates, and can transfer Neu5Ac to both alpha-galactoside and beta-galactoside, efficiently. To elucidate the structural basis for the broad acceptor substrate specificity, we determined the crystal structure of the alpha2,3-sialyltransferase in complex with CMP. The overall structure belongs to the glycosyltransferase-B structural group. We could model a reasonable active conformation structure based on the crystal structure. The predicted structure suggested that the broad substrate specificity could be attributed to the wider entrance of the acceptor substrate binding site.
- Published
- 2009
- Full Text
- View/download PDF
30. Escape mutation selected by Gag28-36-specific cytotoxic T cells in HLA-A*2402-positive HIV-1-infected donors.
- Author
-
Koizumi H, Iwatani T, Tanuma J, Fujiwara M, Izumi T, Oka S, and Takiguchi M
- Subjects
- Cells, Cultured, Epitopes, T-Lymphocyte genetics, Epitopes, T-Lymphocyte immunology, HIV-1 genetics, Humans, gag Gene Products, Human Immunodeficiency Virus genetics, HIV Infections virology, HIV-1 immunology, HLA-A Antigens genetics, Mutation, Missense, Selection, Genetic, T-Lymphocytes, Cytotoxic immunology, gag Gene Products, Human Immunodeficiency Virus immunology
- Abstract
Gag-specific CTLs are known to have stronger ability to control HIV-1 replication than others that are protein-specific. Therefore, the analysis of Gag escape mutants is expected to clarify the mechanisms of immune control in HIV-1-infected donors. However, only a limited number of Gag escape mutants have been identified so far. A previous study suggested the possibility that Gag28-3R (KW9-3R) is an escape mutant from HLA-A*2402-restricted KW9-specific CTLs but did not show any evidence of it. Here we sought to demonstrate that KW9-3R is selected as escape mutant by KW9-specific CTLs. KW9-specific CTLs showed a remarkable reduction in recognition of target cells infected with the KW9-3R mutant. The sequence analysis of HIV-1 from 58 HIV-1-infected individuals showed that the frequency of the KW9-3R mutant was significantly higher in HLA-A*2402(+) individuals than in HLA-A*2402(-) individuals. Longitudinal analysis of an HLA-A*2402(+) individual with HIV-1 early infection showed that this escape mutant was selected over an approximately 2-year period. These results together indicate that Gag28-3R is an escape mutant selected by HLA-A*2402-restricted KW9-specific CTLs. Further analysis of this epitope will clarify the role of HIV-1-specific CTLs in the control of HIV-1 among the Japanese population, since 70% of them carry this allele.
- Published
- 2009
- Full Text
- View/download PDF
31. Putative tumor suppressor EDD interacts with and up-regulates APC.
- Author
-
Ohshima R, Ohta T, Wu W, Koike A, Iwatani T, Henderson M, Watts CK, and Otsubo T
- Subjects
- Adenomatous Polyposis Coli metabolism, Adenomatous Polyposis Coli pathology, Colorectal Neoplasms genetics, Drosophila Proteins, Gene Expression Regulation, Neoplastic, Genes, Tumor Suppressor, HeLa Cells, Humans, Trans-Activators metabolism, Tumor Suppressor Proteins genetics, Ubiquitin-Protein Ligases, Wnt1 Protein physiology, beta Catenin, Adenomatous Polyposis Coli immunology, Adenomatous Polyposis Coli Protein physiology, Tumor Suppressor Proteins metabolism, Up-Regulation
- Abstract
Adenomatous polyposis coli (APC), whose mutation causes colorectal cancers, is a key player in the Wnt signaling pathway. While the role of APC in inhibition of beta-catenin/LEF1-dependent activation of transformation-inducing genes has been intensively studied and well established, regulation of APC expression at the protein level is only partially understood. Here we report that APC is up-regulated by EDD, the mammalian orthologue of Drosophila melanogaster"hyperplastic discs" gene (hyd) that is considered to be a putative tumor suppressor. Screening of APC immunocomplexes by mass spectrometry identified EDD as a putative APC-interacting protein. Exogenously expressed and endogenous APC interacted with EDD in vivo. Indirect immunofluorescent analyses demonstrated that APC and EDD co-localized in the cytoplasm of the cell. Over-expression of EDD enhanced the protein expression level of APC and its binding partner Axin, resulting in inhibition of Wnt signaling downstream of beta-catenin. Conversely, siRNA knock-down of EDD down-regulated APC at the protein level without altering its mRNA level, causing enhanced protein expression of beta-catenin. Thus, through protein-protein interaction, EDD stabilizes APC and up-regulates APC's function to inhibit beta-catenin, suggesting that EDD could act as a colorectal tumor suppressor.
- Published
- 2007
- Full Text
- View/download PDF
32. Species difference of (2R,4R)-2-(o-hydroxyphenyl)-3-(3-mercaptopropionyl)-4-thiazolidinec arb oxylic acid (SA446) in inhibition of angiotensin converting enzyme.
- Author
-
Nakata K, Iwatani T, Horiuchi M, Kito H, Yamauchi H, and Iso T
- Subjects
- 3-Mercaptopropionic Acid analogs & derivatives, 3-Mercaptopropionic Acid blood, Angiotensin I antagonists & inhibitors, Animals, Blood Pressure drug effects, Blood Proteins metabolism, Cats, Dogs, Female, Guinea Pigs, Male, Protein Binding, Rabbits, Rats, Rats, Inbred Strains, Species Specificity, Sulfhydryl Compounds, Thiazolidines, 3-Mercaptopropionic Acid pharmacology, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents pharmacology
- Abstract
A marked species difference was observed both in vitro and in vivo in the activity of SA446, an orally active inhibitor of angiotensin converting enzyme (ACE), as compared with that of captopril in five different animal species. The activity of SA446 in vitro in inhibiting plasma ACE correlated with the activity in vivo as determined by inhibition of the pressor response to angiotensin I (AI). SA446 was more potent as an inhibitor of AI response in dogs, cats and rabbits than in guinea pigs and rats. Furthermore, ACE activity in whole blood in vivo was inhibited by SA446, and the activity of SA446 was also more potent in dogs than in rats. The concentration of SA446 in the ultrafiltrate of blood (free form) was significantly higher in dogs than in rats, while no difference was observed in level of SA446 in the whole blood (free and protein-bound form) between these two species after intravenous injection. The binding rate of SA446 to plasma protein of rats in vitro was more than twice as high as that of dogs. These results suggest that the difference in the protein binding rate of SA446 is reflected in ultrafiltrate level and is one of the important components in defining the species difference in SA446 action.
- Published
- 1986
- Full Text
- View/download PDF
33. Determination of SA-446 in human whole blood and urine by electron capture-gas liquid chromatography.
- Author
-
Iwatani T, Naitoh M, Takashina H, Nagamori S, Itoh Y, and Iwao J
- Subjects
- 3-Mercaptopropionic Acid analogs & derivatives, Chromatography, Gas methods, Humans, Sulfhydryl Compounds, Thiazolidines, 3-Mercaptopropionic Acid analysis, Angiotensin-Converting Enzyme Inhibitors
- Published
- 1982
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.